ArticleOpen forum infectious diseases2020
Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Seroprevalence of SARS-CoV-2 antibodies in Ethiopia: findings from the 2022 national population-based survey (second round).BMC infectious diseases · 2025Article
- The Global COVID-19 Pandemic Experience: Innovation Through Environmental Assessment and Seropositivity Surveillance.International journal of environmental research and public health · 2025Article
- Genomic epidemiology of SARS-CoV-2 variants during the first two years of the pandemic in Colombia.Communications medicine · 2023Article
- COVID-19 in Latin America and the Caribbean: Two years of the pandemic.Journal of internal medicine · 2022Review
- Seroprevalence of IgM and IgG anti-SARS-COV-2 and associated factors among agricultural workers in Colombia.New microbes and new infections · 2022Article
- COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the General Population of the Capital City Tunis.Diagnostics (Basel, Switzerland) · 2022Article
- High Prevalence of SARS-CoV-2 in an Indigenous Community of the Colombian Amazon Region.Tropical medicine and infectious disease · 2021Article
- COVID-19 spread, detection, and dynamics in Bogota, Colombia.Nature communications · 2021Article
- The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- Seroprevalence of SARS-CoV-2 Infection among Occupational Groups from the Bucaramanga Metropolitan Area, Colombia.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A serological survey was carried out in Monteria (500 000 population), a mid-size city in Colombia. An overall prevalence of 55.3% (95% confidence interval, 52.5%-57.8%) was found among a sample of 1.368 people randomly selected from the population. Test positivity was related to economic characteristics with the highest prevalence found in the most impoverished areas, representing 83.8% of the city's population. We found a prevalence that might be associated with some important level of population immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.